Starton's Strategic Platform: Continuous Drug Delivery Changing Patient Outcomes for the Better
The presentation will focus on the company’s preparation for its STAR-LLD Phase 1 clinical studies and STAR-OLZ Phase 2 clinical studies scheduled to start early 2022.
https://startontherapeutics.app.dealmaker.tech/invitations/starton_506c/view
- Starton’s strategic platform: new indications and opportunities to replace the standard of care.
- Near-term major clinical milestones - lead program entering Phase 1.
- Recent accomplishments to establish proof of concepts and strong IP.
- Current capital raise and public listing strategy.
Recording
Attachments
Speakers
About
Starton is a clinical-stage biotechnology company transforming standard of care therapies with proprietary dermal delivery technology, so people with cancer can receive continuous treatment to live better, longer. Starton's strategic platform targets new indications and opportunities to replace the standard of care. Two programs entering clinical development: STAR-LLD in hematologic malignancies (blood cancers, Phase 1) and STAR-OLZ in cancer supportive care (CINV, Phase 2). The experienced Board and management team includes world-renowned scientific leaders in their field leading each program.